Literature DB >> 29420120

Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.

Shahrokh Izadi1, Seyed Mohsen Zahraei2, Talat Mokhtari-Azad3.   

Abstract

Eight months after the mass immunization campaign of November 2015 against measles and rubella in the southeast of Iran, in order to evaluate the sero-immunity level of the people living in the mentioned region, a serosurvey study was performed. Using a multi-stage probability proportional to size cluster sampling, the sera of 1,056 participants, ranging from 15 months to 20 years old, were tested for measles and rubella IgG antibodies in the National Reference Laboratory at Tehran University of Medical Sciences, Tehran, Iran. The seroprevalence rates of antibodies against measles and rubella in the age groups below 16 years were respectively 98.4 and 93.2%. In the age group of 16 to 20 years, who was not the target of the mass immunization campaign, the said rates were respectively 91.7% and 87.4%. The herd immunity of the age groups below 16 years, who were the target of the campaign, is favourably high and reassuring both for measles and for rubella. Campaigns of supplementary vaccination play a substantial role for filling the gaps in the herd immunity.

Entities:  

Keywords:  Herd immunity; Immunization; Iran; Measles; Rubella; Seroprevalence; Vaccination

Mesh:

Substances:

Year:  2018        PMID: 29420120      PMCID: PMC6037465          DOI: 10.1080/21645515.2018.1436920

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  14 in total

Review 1.  IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy.

Authors:  Mikko Paunio; Klaus Hedman; Irja Davidkin; Heikki Peltola
Journal:  Expert Opin Pharmacother       Date:  2003-08       Impact factor: 3.889

2.  A simplified general method for cluster-sample surveys of health in developing countries.

Authors:  S Bennett; T Woods; W M Liyanage; D L Smith
Journal:  World Health Stat Q       Date:  1991

Review 3.  Evolution and Use of Dynamic Transmission Models for Measles and Rubella Risk and Policy Analysis.

Authors:  Kimberly M Thompson
Journal:  Risk Anal       Date:  2016-06-09       Impact factor: 4.000

4.  Rubella vaccines: WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2011-07-15

5.  Progress towards measles elimination in Bangladesh, 2000–2016.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-07-21

6.  Documentation of Measles Elimination in Iran: Evidences from 2012 to 2014.

Authors:  Manoochehr Karami; Seyed Mohsen Zahraei; Azam Sabouri; Rambod Soltanshahi; Azam Biderafsh; Naser Piri; Jong-Koo Lee
Journal:  J Res Health Sci       Date:  2017-08-05

7.  Prevalence of measles antibody in children of different ages in Shiraz, Islamic Republic of Iran.

Authors:  A Karimi; A Arjomandi; A Alborzi; M Rasouli; M R Kadivar; B Obood; B Pourabbas
Journal:  East Mediterr Health J       Date:  2004 Jul-Sep       Impact factor: 1.628

8.  Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran.

Authors:  Seyed Mohsen Zahraei; Shahrokh Izadi; Talat Mokhtari-Azad
Journal:  Hum Vaccin Immunother       Date:  2016-07-26       Impact factor: 3.452

9.  Progress in measles and rubella elimination in Iran.

Authors:  Abdoulreza Esteghamati; Mohammad Mehdi Gouya; Seyed Mohsen Zahraei; Mohammad Nasr Dadras; Armin Rashidi; Frank Mahoney
Journal:  Pediatr Infect Dis J       Date:  2007-12       Impact factor: 2.129

10.  Congenital rubella syndrome in Iran.

Authors:  Jila Sadighi; Hasan Eftekhar; Kazem Mohammad
Journal:  BMC Infect Dis       Date:  2005-06-06       Impact factor: 3.090

View more
  4 in total

1.  Reiteration of the elimination status of measles in the southeast of Iran, 2015.

Authors:  Shahrokh Izadi; Masoome Arabsalmani; Mahdi Mohammadi; Seyed Mehdi Tabatabaei; Ali-Akbar Haghdoost
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

2.  Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.

Authors:  Manoj V Murhekar; Nivedita Gupta; Alvira Z Hasan; Muthusamy Santhosh Kumar; V Saravana Kumar; Christine Prosperi; Gajanan N Sapkal; Jeromie Wesley Vivian Thangaraj; Ojas Kaduskar; Vaishali Bhatt; Gururaj Rao Deshpande; Ullas Padinjaremattathil Thankappan; Avi Kumar Bansal; Sanjay L Chauhan; Gangandeep Singh Grover; Arun Kumar Jain; Ragini N Kulkarni; Santanu Kumar Sharma; Itta K Chaaithanya; Sanchit Kharwal; Sunil K Mishra; Neha R Salvi; Sandeep Sharma; Nilanju P Sarmah; R Sabarinathan; Augustine Duraiswamy; D Sudha Rani; K Kanagasabai; Abhishek Lachyan; Poonam Gawali; Mitali Kapoor; Arpit Kumar Shrivastava; Saurabh Kumar Chonker; Bipin Tilekar; Babasaheb V Tandale; Mohammad Ahmad; Lucky Sangal; Amy Winter; Sanjay M Mehendale; William J Moss; Kyla Hayford
Journal:  Lancet Glob Health       Date:  2022-11       Impact factor: 38.927

3.  Estimation of measles risk using the World Health Organization Measles Programmatic Risk Assessment Tool, Iran.

Authors:  Abolfazl Mohammadbeigi; Seyed Mohsen Zahraei; Azadeh Asgarian; Sima Afrashteh; Narges Mohammadsalehi; Salman Khazaei; Hossein Ansari
Journal:  Heliyon       Date:  2018-11-01

4.  Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.

Authors:  Hana Saffar; Maryam Khalifeloo; Mohammad-Jafar Saffar; Alireza Abdollahi; Mohammad-Reza Parsaei; Gholam-Reza Ghorbani; Samaneh Salarvand; Mohsen Aarabi
Journal:  BMC Infect Dis       Date:  2021-03-25       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.